Top 5 Drug Type | Count |
---|---|
Small molecule drug | 13 |
Natural Killer Cell Therapies | 1 |
Chemical drugs | 1 |
Therapeutic vaccine | 1 |
Prophylactic vaccine | 1 |
Mechanism Akt-1 inhibitors [+4] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GSK-3β inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism CLPP agonists [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date01 May 2025 |
Sponsor / Collaborator [+4] |
Start Date16 Apr 2025 |
Sponsor / Collaborator [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Elraglusib ( GSK-3β ) | Colorectal Cancer More | Phase 1 |
ONC-206 ( CLPP x D2 receptor x D3 receptor x ERK ) | Biliary Tract Neoplasms More | Preclinical |
ONC-212 ( CLPP x D2 receptor x D3 receptor x ERK x GPR132 ) | Radiation esophagitis More | Preclinical |
CB001(Brown University) ( CFLAR ) | Melanoma More | Preclinical |
MO-I-1182 ( HAAH ) | Breast Cancer More | Preclinical |